Renal cancer | Guidance and guideline topic | NICE

5 new

and

0 updated

products since January 2017.

NICE Pathways - mapping our guidance

Technology appraisal guidance

Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment (TA333) February 2015
Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma (TA178) August 2009
Everolimus for advanced renal cell carcinoma after previous treatment (TA432) February 2017
Nivolumab for previously treated advanced renal cell carcinoma (TA417) November 2016
Pazopanib for the first-line treatment of advanced renal cell carcinoma (TA215) February 2011
Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma (TA169) March 2009

NICE Guidelines

Improving outcomes in urological cancers (CSG2) September 2002
Suspected cancer: recognition and referral (NG12) June 2015

Interventional procedures guidance

Irreversible electroporation for treating renal cancer (IPG443) February 2013
Laparoscopic cryotherapy for renal cancer (IPG405) August 2011
Laparoscopic nephrectomy (including nephroureterectomy) (IPG136) August 2005
Laparoscopic partial nephrectomy (IPG151) January 2006
Percutaneous cryotherapy for renal cancer (IPG402) July 2011
Percutaneous radiofrequency ablation for renal cancer (IPG353) July 2010
Single-port laparoscopic nephrectomy (IPG414) November 2011

Quality standards

Suspected cancer (QS124) June 2016

In development

Cabozantinib for treating renal cell carcinoma [ID931] (GID-TA10075) August 2017 Technology appraisal guidance
Nivolumab with ipilimumab for untreated metastatic renal cell carcinoma [ID1182] (GID-TA10189) TBC Technology appraisal guidance
Renal cell carcinoma - sunitinib [ID1076] (GID-TA10166) TBC Technology appraisal guidance
Tivozanib for treating renal cell carcinoma [ID591] (GID-TA10123) December 2017 Technology appraisal guidance